EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Sold by Essex Woodlands Management Inc.

Essex Woodlands Management Inc. reduced its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 24.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,169,857 shares of the company's stock after selling 381,664 shares during the quarter. EyePoint Pharmaceuticals makes up approximately 2.0% of Essex Woodlands Management Inc.'s investment portfolio, making the stock its 4th largest position. Essex Woodlands Management Inc. owned approximately 1.71% of EyePoint Pharmaceuticals worth $8,715,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in EYPT. Federated Hermes Inc. boosted its position in EyePoint Pharmaceuticals by 92.7% in the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock valued at $27,620,000 after buying an additional 1,783,765 shares during the period. Vanguard Group Inc. boosted its holdings in shares of EyePoint Pharmaceuticals by 24.8% in the fourth quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock valued at $28,334,000 after purchasing an additional 755,045 shares during the period. Finepoint Capital LP boosted its holdings in shares of EyePoint Pharmaceuticals by 57.1% in the fourth quarter. Finepoint Capital LP now owns 1,111,104 shares of the company's stock valued at $8,278,000 after purchasing an additional 403,700 shares during the period. Franklin Resources Inc. grew its stake in EyePoint Pharmaceuticals by 9.9% in the third quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company's stock worth $32,056,000 after purchasing an additional 362,399 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in EyePoint Pharmaceuticals by 1,171.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 371,758 shares of the company's stock worth $2,970,000 after purchasing an additional 342,516 shares during the period. 99.41% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on EYPT. Chardan Capital reissued a "buy" rating and set a $33.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. StockNews.com upgraded shares of EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Citigroup initiated coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $33.00 target price on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $26.63.

EyePoint Pharmaceuticals Trading Down 1.6 %

Shares of NASDAQ:EYPT traded down $0.11 during trading on Thursday, reaching $6.60. The stock had a trading volume of 249,530 shares, compared to its average volume of 840,341. The company has a market capitalization of $453.68 million, a P/E ratio of -3.31 and a beta of 1.39. The firm's 50-day simple moving average is $5.93 and its 200 day simple moving average is $7.79. EyePoint Pharmaceuticals, Inc. has a one year low of $3.91 and a one year high of $21.25.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its earnings results on Wednesday, March 5th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.10). The firm had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million. EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. Equities research analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.